Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Eton Pharmaceuticals Inc
ETON | US
27.12
USD1.07
4.11%
ETON | US
About Eton Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
27.12
Open
26.06
High
27.14
Low
26.05
Eton Pharmaceuticals Inc. a specialty pharmaceutical company focuses on developing acquiring and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis; Alaway Preservative Free a preservative-free ophthalmic product to treat allergic conjunctivitis; EPRONTIA a liquid formulation of topiramate; ZONISADE a liquid formulation of zonisamide for the treatment of partial seizures in patients with epilepsy; and Lamotrigine for Oral Suspension for the treatment of epilepsy. Eton Pharmaceuticals Inc. was incorporated in 2017 and is based in Deer Park Illinois.
View LessETON | US
Risk
62.8
Sharpe
2.35
Luna's Score
52/100
Recommendation
Hold
Luna says (ETON | US)
What's Working
Positive Momentum
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
58.2%1 month
62.8%3 months
51.4%6 months
48.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
23.87
Price to book
16.03
Debt to equity
0.36
Debt to assets
0.15
Ent. to EBITDA
51.26
Ent. to rev.
6.46
PEG
-
Other Fundamentals
EBITDA
-5.31M
MarketCap
700.68M
MarketCap(USD)
700.68M
Div. yield
-
Op. margin
-32.35
Erngs. growth
-12.60
Rev. growth
-24.40
Ret. on equity
-44.30
Short ratio
0.95
Short perc.
0.51
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.96
Range1M
8.57
Range3M
12.92
Volumes: Market Activity
Rel. volume
0.53
Price X volume
7.08M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 51.26 | - | Expensive |
| Ent. to Revenue | 6.46 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 16.03 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 51.35 | - | Lower Risk |
| Debt to Equity | 0.36 | -1.23 | Expensive |
| Debt to Assets | 0.15 | 0.25 | Cheaper |
| Market Cap | 700.68M | - | Emerging |
